<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Warnick, Aaron</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Q&amp;amp;A with vaccine developer Adrian Hill: ‘Why shouldn’t we have a big push on malaria?’</style></title><secondary-title><style face="normal" font="default" size="100%">The Nation's Health</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-16</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">Adrian Hill, FMedSci, FRCP, FRS, is director of the Jenner Institute and co-director of the Oxford Martin Program on Vaccines at Oxford University. He co-led research on the Oxford-AstraZeneca COVID-19 vaccine. In April, his team announced that a candidate malaria vaccine had achieved a 77% efficacy in early clinical trials. The vaccine is now in Phase III clinical trials involving a larger population and additional benchmarks on safety and effectiveness.</style></abstract></record></records></xml>